JP5557528B2 - 末梢性神経障害の治療方法 - Google Patents
末梢性神経障害の治療方法 Download PDFInfo
- Publication number
- JP5557528B2 JP5557528B2 JP2009527207A JP2009527207A JP5557528B2 JP 5557528 B2 JP5557528 B2 JP 5557528B2 JP 2009527207 A JP2009527207 A JP 2009527207A JP 2009527207 A JP2009527207 A JP 2009527207A JP 5557528 B2 JP5557528 B2 JP 5557528B2
- Authority
- JP
- Japan
- Prior art keywords
- agent
- protein
- medicament according
- amino acid
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
文献[19]に開示されているように、EV576は、ヒメダニ類のOrthinodoros moubataの唾液腺抽出物を用いて、古典的溶血アッセイ(図3)により補体阻害活性があることが判明した唾液腺抽出物フラクションをSDS−PAGE及びRP−HPLCに付すことにより精製した。
文献[20]に記載された方法に従ってラットに実験的自己免疫神経炎(EAN)を誘発させた。
[2] Kwa., et. al., Brain 2003. 126, 361-375
[3] Stoll, et. al., Ann Neurol 1991. 30:147-155
[4] Guo, R.F. and P.A. Ward, Annu Rev Immunol, 2005. 23: p. 821-52
[5] Neumann, E., et al., Arthritis Rheum, 2002. 46(4): p. 934-45
[6] Williams, A.S., et al., Arthritis Rheum, 2004. 50(9): p. 3035-44
[7] Quigg, R.J., Curr Dir Autoimmun, 2004. 7: p. 165-80
[8] Papagianni, A.A., et al., Nephrol Dial Transplant, 2002. 17(1): p. 57-63
[9] He, C., et al., J Immunol, 2005. 174(9): p. 5750-7
[10] Mead, R.J., et al., J Immunol, 2002. 168(1): p. 458-65
[11] Nakashima, S., et al., J Immunol, 2002. 169(8): p. 4620-7
[12] Mizuno, M. and D.S. Cole, Expert Opin Investig Drugs, 2005. 14(7): p. 807-21
[13] Allegretti, M., et al.. Curr Med Chem, 2005. 12(2): p. 217-36
[14] Terpe K, Appl Microbiol Biotechnol, 2003. 60: 523-33
[15] Sambrook et al (2000)
[16] Fernandez & Hoeffler (1998)
[17] Ausubel et al. (1991)
[18] Remington's Pharmaceutical Sciences; Mack Pub. Co., N.J. 1991
[19] WO2004/106369
[20] Zhu, J. et al. Acta Neurologica Scandinavica, 1994. 90: p. 19-25
Claims (17)
- 被験体における感染後脱髄多発神経根筋障害(ギラン−バレー症候群)を治療又は予防するための医薬であって、補体C5に結合する剤の治療又は予防に有効な量を含み、C5に結合する該剤は、配列番号2のアミノ酸配列の19〜168番アミノ酸を含む若しくはそれから構成されるタンパク質であるか、又は配列番号2のアミノ酸配列と90%を超える同一性を有するアミノ酸配列を含む若しくはそれから構成され、C5に結合するタンパク質である、前記医薬。
- 前記剤は、補体C5がC5コンベルターゼによって補体C5aと補体C5b−9とに分解されるのを防ぐ作用をする、請求項1に記載の医薬。
- 前記剤はIC500.2mg/mL未満でC5に結合する、請求項1又は2に記載の医薬。
- 前記剤は吸血性節足動物に由来する、請求項1〜3のいずれか1項に記載の医薬。
- C5に結合する前記剤は、配列番号2のアミノ酸配列の1〜168番アミノ酸を含む若しくはそれから構成されるタンパク質であるか、又は配列番号2のアミノ酸配列と95%を超える同一性を有するアミノ酸配列を含む若しくはそれから構成され、C5に結合するタンパク質である、請求項1〜4のいずれか1項に記載の医薬。
- 前記剤は、核酸分子によってコードされる、請求項1〜4のいずれか1項に記載の医薬。
- 前記核酸分子は、配列番号1のヌクレオチド配列の53〜507番塩基を含むか又はそれから構成される、請求項6に記載の医薬。
- 前記核酸分子は、配列番号1のヌクレオチド配列の1〜507番塩基を含むか又はそれから構成される、請求項7に記載の医薬。
- 前記被験体は哺乳類である、請求項1〜8のいずれか1項に記載の医薬。
- 前記哺乳類がヒトである、請求項9に記載の医薬。
- 前記剤が、被験体内においてできる限り多くの利用可能なC5に結合するのに十分な用量で投与されるように使用される、請求項1〜10のいずれか1項に記載の医薬。
- 前記剤が、被験体内において全ての利用可能なC5に結合するのに十分な用量で投与されるように使用される、請求項11に記載の医薬。
- 前記剤が、経静脈的に用量13mg/kg投与され、その後12時間ごとに腹腔内に4mg/kg投与されるように使用される、請求項1〜12のいずれか1項に記載の医薬。
- C5に結合する前記剤が、末梢性神経障害の治療のための他の薬物の投与も伴う治療計画の一部として投与されるように使用される、請求項1〜13のいずれか1項に記載の医薬。
- 前記他の薬物は免疫グロブリンである、請求項14に記載の医薬。
- C5に結合する前記剤が、前記他の薬物と同時に、順次的に、又は別々に投与されるように使用される、請求項14又は15に記載の医薬。
- 前記感染後脱髄多発神経根筋障害(ギラン−バレー症候群)は、ミラー・フィッシャー症候群、及び急性炎症性脱髄多発神経根筋障害(AIDP)からなる群から選択される、請求項1〜16のいずれか1項に記載の医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0617734.9 | 2006-09-08 | ||
GBGB0617734.9A GB0617734D0 (en) | 2006-09-08 | 2006-09-08 | Method of treating peripheral nerve disorders |
PCT/GB2007/003401 WO2008029167A1 (en) | 2006-09-08 | 2007-09-10 | Method of treating peripheral nerve disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010502686A JP2010502686A (ja) | 2010-01-28 |
JP5557528B2 true JP5557528B2 (ja) | 2014-07-23 |
Family
ID=37232629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009527207A Active JP5557528B2 (ja) | 2006-09-08 | 2007-09-10 | 末梢性神経障害の治療方法 |
Country Status (11)
Country | Link |
---|---|
US (4) | US9211312B2 (ja) |
EP (1) | EP2061485B1 (ja) |
JP (1) | JP5557528B2 (ja) |
AU (1) | AU2007293239B2 (ja) |
CA (1) | CA2662715C (ja) |
DK (1) | DK2061485T3 (ja) |
ES (1) | ES2397900T3 (ja) |
GB (1) | GB0617734D0 (ja) |
NZ (1) | NZ575461A (ja) |
PL (1) | PL2061485T3 (ja) |
WO (1) | WO2008029167A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
HUE026042T2 (en) * | 2006-10-10 | 2016-05-30 | Regenesance B V | Complement inhibition for improved nerve regeneration |
JP5840623B2 (ja) | 2010-01-08 | 2016-01-06 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 気道のウイルス感染症の治療に用いるev576 |
US9808502B2 (en) | 2012-02-20 | 2017-11-07 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement C5 |
GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
WO2016198133A1 (en) * | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗c5抗体及びそれらの使用 |
EP4272821A3 (en) | 2017-04-03 | 2024-01-03 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
WO2018193122A1 (en) | 2017-04-21 | 2018-10-25 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of autoimmune blistering diseases |
WO2018234118A1 (en) | 2017-06-23 | 2018-12-27 | Inflarx Gmbh | TREATMENT OF INFLAMMATORY DISEASES BY INHIBITORS OF C5A ACTIVITY |
SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
WO2020053206A1 (en) | 2018-09-10 | 2020-03-19 | Volution Immuno Pharmaceuticals Sa | Coversin for use in the treatment of rheumatic diseases |
GB201905810D0 (en) | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
CA3153803A1 (en) | 2019-09-27 | 2021-04-01 | Volution Immuno Pharmaceuticals Sa | Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma) |
KR20220159983A (ko) | 2020-03-27 | 2022-12-05 | 인플라알엑스 게엠베하 | 코로나 바이러스 감염 치료를 위한 C5a의 억제제 |
GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1642983A (zh) * | 2002-01-25 | 2005-07-20 | G2治疗有限公司 | 抗C5aR抗体及其应用 |
ITMI20021527A1 (it) * | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
MXPA05012880A (es) * | 2003-06-02 | 2006-02-22 | Evolutec Ltd | Inhibidores de complemento. |
WO2005023866A2 (en) * | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
CA2662480C (en) | 2006-09-05 | 2016-11-08 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
-
2006
- 2006-09-08 GB GBGB0617734.9A patent/GB0617734D0/en not_active Ceased
-
2007
- 2007-09-10 ES ES07804199T patent/ES2397900T3/es active Active
- 2007-09-10 WO PCT/GB2007/003401 patent/WO2008029167A1/en active Application Filing
- 2007-09-10 CA CA2662715A patent/CA2662715C/en active Active
- 2007-09-10 PL PL07804199T patent/PL2061485T3/pl unknown
- 2007-09-10 US US12/440,462 patent/US9211312B2/en active Active
- 2007-09-10 EP EP07804199A patent/EP2061485B1/en active Active
- 2007-09-10 NZ NZ575461A patent/NZ575461A/en unknown
- 2007-09-10 AU AU2007293239A patent/AU2007293239B2/en active Active
- 2007-09-10 DK DK07804199.3T patent/DK2061485T3/da active
- 2007-09-10 JP JP2009527207A patent/JP5557528B2/ja active Active
-
2015
- 2015-11-12 US US14/939,154 patent/US20160166641A1/en not_active Abandoned
-
2018
- 2018-05-21 US US15/984,881 patent/US20190117730A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/481,528 patent/US20220249608A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ575461A (en) | 2011-11-25 |
EP2061485A1 (en) | 2009-05-27 |
CA2662715A1 (en) | 2008-03-13 |
ES2397900T3 (es) | 2013-03-12 |
US9211312B2 (en) | 2015-12-15 |
US20190117730A1 (en) | 2019-04-25 |
AU2007293239A1 (en) | 2008-03-13 |
DK2061485T3 (da) | 2012-11-19 |
US20100111929A1 (en) | 2010-05-06 |
US20220249608A1 (en) | 2022-08-11 |
AU2007293239B2 (en) | 2012-07-05 |
GB0617734D0 (en) | 2006-10-18 |
JP2010502686A (ja) | 2010-01-28 |
CA2662715C (en) | 2018-04-03 |
WO2008029167A1 (en) | 2008-03-13 |
US20160166641A1 (en) | 2016-06-16 |
PL2061485T3 (pl) | 2013-03-29 |
EP2061485B1 (en) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5557528B2 (ja) | 末梢性神経障害の治療方法 | |
JP5254792B2 (ja) | 重症筋無力症の治療方法 | |
JP5784078B2 (ja) | 呼吸器疾患の治療方法 | |
RU2700932C2 (ru) | Ornithodoros moubata игибитор комплемента, предназначенный для лечения опосредованных комплементом заболеваний пациента с полиморфизмом с5 комплемента | |
AU2016203058A1 (en) | EV576 for use in the treatment of viral infections of the respiratory tract | |
EP1303288A1 (en) | Mannan-binding lectin (mbl) treatment of infections in individuals treated with tnf-alfa inhibitors | |
DK2061501T3 (en) | METHOD OF TREATING RESPIRATORY DISORDERS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121029 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121221 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130312 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130607 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130614 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130711 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130723 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130731 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130910 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131204 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131211 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140603 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5557528 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |